MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
4.915
-0.155
-3.06%
Opening 11:26 10/05 EDT
OPEN
4.980
PREV CLOSE
5.07
HIGH
5.02
LOW
4.789
VOLUME
199.76K
TURNOVER
530.48K
52 WEEK HIGH
11.49
52 WEEK LOW
3.120
MARKET CAP
769.46M
P/E (TTM)
-4.1745
1D
5D
1M
3M
1Y
5Y
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold
Benzinga · 09/23 16:02
Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
A phase 3 trial of Pfizer (NYSE:PFE) and Sangamo Therapeutics (<span c...
Seekingalpha · 09/22 21:38
Pfizer, Sangamo Therapeutics Announce Phase 3 Trial Of Investigational Gene Therapy For Hemophilia A Has Re-Opened Recruitment
Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened
Benzinga · 09/22 21:05
Intellia falls as analysts react to CRISPR readouts
Gene-editing company Intellia Therapeutics, Inc. (NASDAQ:NTLA</spa...
Seekingalpha · 09/16 16:16
SGMO, CAR and TWST are among after hour movers
Gainers: Coupa Software (COUP) +13%. Fusion Phar...
Seekingalpha · 09/06 21:21
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/30 22:07
Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile
Benzinga · 08/30 12:50
Sangamo gene therapy for Fabry disease shows promise in phase 1/2 trial
Sangamo Therapeutics (NASDAQ:SGMO) <a href="https://seekinga...
Seekingalpha · 08/30 10:52
More
About SGMO
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.